HK1244009A1 - 對血清白蛋白具有結合特異性的經設計的錨蛋白重複結構域 - Google Patents

對血清白蛋白具有結合特異性的經設計的錨蛋白重複結構域

Info

Publication number
HK1244009A1
HK1244009A1 HK18103392.8A HK18103392A HK1244009A1 HK 1244009 A1 HK1244009 A1 HK 1244009A1 HK 18103392 A HK18103392 A HK 18103392A HK 1244009 A1 HK1244009 A1 HK 1244009A1
Authority
HK
Hong Kong
Prior art keywords
serum albumin
binding specificity
ankyrin repeat
repeat domains
designed ankyrin
Prior art date
Application number
HK18103392.8A
Other languages
English (en)
Inventor
Talitha Bakker
Michael T Stumpp
Hans Kaspar Binz
Douglas Phillips
Ignacio Dolado
Patrik Forrer
Frieder W Merz
Ivo Sonderegger
Daniel Steiner
Maya Gulotti-Georgieva
Saliba Johan Abram
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of HK1244009A1 publication Critical patent/HK1244009A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
HK18103392.8A 2015-04-02 2018-03-12 對血清白蛋白具有結合特異性的經設計的錨蛋白重複結構域 HK1244009A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15162511 2015-04-02
EP15162502 2015-04-02
PCT/EP2016/057272 WO2016156596A1 (en) 2015-04-02 2016-04-01 Designed ankyrin repeat domains with binding specificity for serum albumin

Publications (1)

Publication Number Publication Date
HK1244009A1 true HK1244009A1 (zh) 2018-07-27

Family

ID=55650423

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103392.8A HK1244009A1 (zh) 2015-04-02 2018-03-12 對血清白蛋白具有結合特異性的經設計的錨蛋白重複結構域

Country Status (21)

Country Link
US (3) US9458211B1 (zh)
EP (2) EP4272838A3 (zh)
JP (1) JP6552636B2 (zh)
KR (2) KR20220109488A (zh)
CN (1) CN107454904A (zh)
AU (3) AU2016240220B2 (zh)
BR (1) BR112017020986A2 (zh)
CA (1) CA2979602C (zh)
CL (1) CL2017002454A1 (zh)
CO (1) CO2017009954A2 (zh)
ES (1) ES2953482T3 (zh)
HK (1) HK1244009A1 (zh)
IL (2) IL276944B (zh)
MX (2) MX2022008302A (zh)
MY (1) MY179505A (zh)
NZ (1) NZ735803A (zh)
PH (1) PH12017501792A1 (zh)
RU (1) RU2769470C2 (zh)
SA (1) SA517390092B1 (zh)
SG (1) SG11201707606RA (zh)
WO (1) WO2016156596A1 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
JP6105479B2 (ja) * 2010-11-26 2017-03-29 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 血清アルブミンに結合する設計リピートタンパク質
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)
AR109680A1 (es) * 2016-09-22 2019-01-09 Molecular Partners Ag Proteínas recombinantes y sus usos
CN110959015B (zh) * 2017-07-12 2023-07-25 四川科伦博泰生物医药股份有限公司 双特异性重组蛋白
JP2021500851A (ja) * 2017-08-18 2021-01-14 ケンブリッジ・エンタープライズ・リミテッドＣａｍｂｒｉｄｇｅ Ｅｎｔｅｒｐｒｉｓｅ Ｌｉｍｉｔｅｄ モジュラー結合タンパク質
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
WO2020198074A1 (en) * 2019-03-22 2020-10-01 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
AU2020286600A1 (en) * 2019-06-04 2021-12-23 Molecular Partners Ag Recombinant FAP binding proteins and their use
BR112021024237A2 (pt) * 2019-06-04 2022-04-19 Molecular Partners Ag Domínio de repetição de anquirina projetado com estabilidade aprimorada
CA3139051A1 (en) * 2019-06-04 2020-12-10 Christian REICHEN Multispecific proteins
CA3139041A1 (en) 2019-06-04 2020-12-10 Christian REICHEN Recombinant 4-1bb binding proteins and their use
AU2020399230A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Recombinant peptide-MHC complex binding proteins and their generation and use
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
IL297940A (en) 2020-05-06 2023-01-01 Molecular Partners Ag New ankyrin repeat binding proteins and their uses
AU2021271129A1 (en) 2020-05-14 2022-12-15 Molecular Partners Ag Multispecific proteins
WO2021229076A1 (en) 2020-05-14 2021-11-18 Molecular Partners Ag Recombinant cd40 binding proteins and their use
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
WO2022130300A1 (en) 2020-12-16 2022-06-23 Molecular Partners Ag Novel slow-release prodrugs
EP4263608A1 (en) 2020-12-16 2023-10-25 Molecular Partners AG Recombinant cd3 binding proteins and their use
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
KR20230155464A (ko) 2021-03-09 2023-11-10 몰리큘라 파트너스 아게 신규한 DARPin-기반 다중특이성 T-세포 인게이저
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
CA3239407A1 (en) 2021-12-14 2023-06-22 Simon FONTAINE Designed repeat domains with dual binding specificity and their use
CN114957426B (zh) * 2022-06-02 2023-05-16 华南师范大学 Sp6rars及其在防治蜚蠊目昆虫中的应用
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
JP5042218B2 (ja) 2005-07-08 2012-10-03 ユニバーシティ・オブ・チューリッヒ 融合ポリペプチドの翻訳と同時のトランスロケーションを使用するファージディスプレイ
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
DK2173890T3 (da) 2007-06-21 2011-06-27 Univ Muenchen Tech Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro
EP2198022B1 (en) 2007-09-24 2024-03-06 University Of Zurich Designed armadillo repeat proteins
CN102272148A (zh) 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
WO2011095545A1 (en) 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
TWI510246B (zh) * 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
MY161679A (en) * 2010-07-09 2017-05-15 Affibody Ab Polypeptides
MX2013000672A (es) * 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar un paciente con probabilidad incrementada de responder a una terapia anti-cancer.
US20130236467A1 (en) * 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
JP6105479B2 (ja) 2010-11-26 2017-03-29 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 血清アルブミンに結合する設計リピートタンパク質
BR112013027766A2 (pt) 2011-04-29 2016-11-29 Janssen Biotech Inc proteinas de repetição de ligação de il4/il13 e usos
US9163070B2 (en) 2012-06-28 2015-10-20 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
JP6486908B2 (ja) * 2013-05-31 2019-03-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 肝細胞増殖因子に結合する設計アンキリン反復タンパク質

Also Published As

Publication number Publication date
SG11201707606RA (en) 2017-10-30
KR20220109488A (ko) 2022-08-04
RU2017134456A3 (zh) 2019-10-08
JP6552636B2 (ja) 2019-07-31
AU2016240220A1 (en) 2017-10-19
ES2953482T3 (es) 2023-11-13
RU2769470C2 (ru) 2022-04-01
MX2022008302A (es) 2023-02-28
EP4272838A2 (en) 2023-11-08
IL276944A (en) 2020-10-29
CA2979602C (en) 2022-12-20
EP3277711A1 (en) 2018-02-07
IL276944B (en) 2022-07-01
PH12017501792A1 (en) 2019-01-21
US20160362453A1 (en) 2016-12-15
CA2979602A1 (en) 2016-10-06
SA517390092B1 (ar) 2022-03-03
IL254788B (en) 2020-09-30
IL254788A0 (en) 2017-12-31
EP3277711B1 (en) 2023-06-07
MY179505A (en) 2020-11-09
AU2016240220B2 (en) 2019-11-21
KR102427117B1 (ko) 2022-07-29
CO2017009954A2 (es) 2018-02-20
US11332501B2 (en) 2022-05-17
AU2021286418A1 (en) 2022-01-20
EP3277711B9 (en) 2023-08-16
US9458211B1 (en) 2016-10-04
EP4272838A3 (en) 2024-01-10
US10155791B2 (en) 2018-12-18
WO2016156596A1 (en) 2016-10-06
KR20170131515A (ko) 2017-11-29
US20160289285A1 (en) 2016-10-06
AU2020201264A1 (en) 2020-03-12
BR112017020986A2 (pt) 2018-08-14
US20190263869A1 (en) 2019-08-29
CN107454904A (zh) 2017-12-08
CL2017002454A1 (es) 2018-05-25
NZ735803A (en) 2021-12-24
JP2018511327A (ja) 2018-04-26
AU2021286418B2 (en) 2024-01-04
RU2017134456A (ru) 2019-04-03
EP3277711C0 (en) 2023-06-07
MX2017012485A (es) 2018-04-11

Similar Documents

Publication Publication Date Title
IL276944A (en) Designed regions containing ankyrin repeats with specific binding to serum albumin
IL263102A (en) A serum albumin-binding protein with a single site
IL267894A (en) Improved serum albumin binding agents
IL267897A (en) Improved serum albumin binding agents
ZA201804317B (en) Altered april binding antibodies
HK1251650A1 (zh) 用於確定同時結合的基於細胞的fret測定法
DK3374392T3 (da) Forbedrede serumalbuminbindende variable immunglobulindomæner
HK1250737A1 (zh) 結合cd79的抗體分子
ZA201701912B (en) Antigen binding proteins that bind cxcr5
ZA201706272B (en) IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
HK1231497A1 (zh) 表現不同結合特徵的 抗原結合蛋白
IL256298A (en) Multi-specific binding proteins
IL250629A0 (en) Antigen-binding proteins that bind cxcr3
ZA201901862B (en) Modified factor h binding protein
IL267318A (en) link test
GB201615588D0 (en) TSLP Binding Proteins
GB201614627D0 (en) Antigen binding proteins
HUP1600456A2 (en) Novel cell-based tnf-alpha binding assay
IL235702A0 (en) Materials and methods for binding myelin binding proteins